Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Has Average Target Price of $75.71

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received an average rating of “Moderate Buy” from the twenty-three brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nineteen have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $75.00.

IONS has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Ionis Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, November 16th. Royal Bank Of Canada reduced their target price on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a report on Tuesday, November 10th. JPMorgan Chase & Co. decreased their price target on Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 22nd. Oppenheimer dropped their price target on Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, November 10th. Finally, HC Wainwright dropped their price target on Ionis Pharmaceuticals from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, November 10th.

Get Our Latest Report on Ionis Pharmaceuticals

Trending Headlines about Ionis Pharmaceuticals

Here are a few of the latest headlines about IONS:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite lowering its earnings forecasts. Ionis analyst estimates
  • Negative Sentiment: HC Wainwright lowered its earnings estimates across several periods. Its FY2027 loss estimate widened to $1.94 per share from $1.25, and it also cut estimates for Q4 2026 and Q1–Q3 2027. The downward revisions could reinforce concerns about Ionis’s path to profitability. Ionis analyst estimates
  • Negative Sentiment: Guggenheim also cut its price target for Ionis, adding to the bearish analyst news; the report provided here does not specify the new target. Ionis Pharmaceuticals stock price target cut by Guggenheim

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Shannon L. Devers sold 1,357 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the transaction, the executive vice president directly owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden bought 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 10th. The shares were bought at an average price of $29.64 per share, for a total transaction of $148,200.00. Following the completion of the transaction, the director directly owned 27,000 shares of the company’s stock, valued at $800,280. This represents a 22.73% increase in their position. The SEC filing for this purchase provides additional information. 1.81% of the stock is owned by corporate insiders.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth $483,000. Allworth Financial LP boosted its position in Ionis Pharmaceuticals by 537.6% in the 3rd quarter. Allworth Financial LP now owns 3,290 shares of the company’s stock valued at $147,000 after buying an additional 2,774 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $423,000. Quarry LP increased its stake in shares of Ionis Pharmaceuticals by 6,796.6% in the 3rd quarter. Quarry LP now owns 2,000 shares of the company’s stock valued at $89,000 after buying an additional 1,971 shares during the period. Finally, Aquatic Capital Management LLC increased its stake in shares of Ionis Pharmaceuticals by 39.9% in the 3rd quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock valued at $2,659,000 after buying an additional 16,980 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Trading Down 2.3%

Shares of Ionis Pharmaceuticals stock opened at $26.58 on Friday. Ionis Pharmaceuticals has a 12-month low of $26.53 and a 12-month high of $86.74. The stock has a market capitalization of $4.43 billion, a P/E ratio of -8.01 and a beta of 0.43. The company has a 50-day simple moving average of $40.76 and a 200 day simple moving average of $63.17. The company has a quick ratio of 5.36, a current ratio of 5.43 and a debt-to-equity ratio of 3.42.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. The firm had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.80) earnings per share. Research analysts expect that Ionis Pharmaceuticals will post -3.48 earnings per share for the current fiscal year.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Recommended Stories

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.